Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 90 12% Improvement Relative Risk Mortality, day 30 14% c19early.org/ace Baldia et al. NCT04321265 Acetaminophen ICU Favors acetaminophen Favors control
The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial
Baldia et al., BMC Geriatrics, doi:10.1186/s12877-022-03709-w, NCT04321265 (history)
Baldia et al., The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19:.., BMC Geriatrics, doi:10.1186/s12877-022-03709-w, NCT04321265
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 2,646 ICU patients ≥70 years old, showing no significant difference in mortality with acetaminophen use in the 10 days prior to ICU admission.
risk of death, 12.0% lower, OR 0.88, p = 0.20, treatment 1,166, control 1,480, adjusted per study, multivariable, day 90, RR approximated with OR.
risk of death, 14.0% lower, OR 0.86, p = 0.20, treatment 1,166, control 1,480, adjusted per study, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Baldia et al., 27 Dec 2022, prospective, multiple countries, peer-reviewed, median age 75.0, 178 authors, trial NCT04321265 (history).
Contact: christian.jung@med.uni-duesseldorf.de (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: (2022) 22:1000 Baldia et al. BMC Geriatrics https://doi.org/10.1186/s12877-022-03709-w Open Access RESEARCH The association of prior paracetamol intake with outcome of very old intensive care patients with COVID‑19: results from an international prospective multicentre trial Philipp Heinrich Baldia1, Bernhard Wernly2, Hans Flaatten3, Jesper Fjølner4, Antonio Artigas5, Bernardo Bollen Pinto6, Joerg C. Schefold7, Malte Kelm1, Michael Beil8, Raphael Romano Bruno1, Stephan Binnebößel1, Georg Wolff1, Ralf Erkens1, Sviri Sigal8, Peter Vernon van Heerden8, Wojciech Szczeklik9, Muhammed Elhadi10, Michael Joannidis11, Sandra Oeyen12, Brian Marsh13, Finn H. Andersen14, Rui Moreno15, Susannah Leaver16, Dylan W. De Lange17, Bertrand Guidet18, Christian Jung1* and COVIP study group Abstract Background: In the early COVID-19 pandemic concerns about the correct choice of analgesics in patients with COVID-19 were raised. Little data was available on potential usefulness or harmfulness of prescription free analgesics, such as paracetamol. This international multicentre study addresses that lack of evidence regarding the usefulness or potential harm of paracetamol intake prior to ICU admission in a setting of COVID-19 disease within a large, prospectively enrolled cohort of critically ill and frail intensive care unit (ICU) patients. Methods: This prospective international observation study (The COVIP study) recruited ICU patients ≥ 70 years admitted with COVID-19. Data on Sequential Organ Failure Assessment (SOFA) score, prior paracetamol intake within 10 days before admission, ICU therapy, limitations of care and survival during the ICU stay, at 30 days, and 3 months. Paracetamol intake was analysed for associations with ICU-, 30-day- and 3-month-mortality using Kaplan Meier analysis. Furthermore, sensitivity analyses were used to stratify 30-day-mortality in subgroups for patient-specific characteristics using logistic regression. Results: 44% of the 2,646 patients with data recorded regarding paracetamol intake within 10 days prior to ICU admission took paracetamol. There was no difference in age between patients with and without paracetamol intake. Patients taking paracetamol suffered from more co-morbidities, namely diabetes mellitus (43% versus 34%, p < 0.001), arterial hypertension (70% versus 65%, p = 0.006) and had a higher score on Clinical Frailty Scale (CFS; IQR 2–5 versus IQR 2–4, p < 0.001). Patients under prior paracetamol treatment were less often subjected to intubation and vasopressor use, compared to patients without paracetamol intake (65 versus 71%, p < 0.001; 63 versus 69%, p = 0.007). Paracetamol intake was not associated with ICU-, 30-day- and 3-month-mortality, remaining true after multivariate adjusted analysis. *Correspondence: christian.jung@med.uni-duesseldorf.de 1 Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany Full list of author information is available at the end of the article © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit